Tech Company Financing Transactions

Ultivue Funding Round

Arch Venture Partners and private investors invested in a $5.2 million Series A funding round for Ultivue. This VC investment round was recorded on 10/14/2015.

Transaction Overview

Company Name
Announced On
10/14/2015
Transaction Type
Venture Equity
Amount
$5,150,000
Round
Series A
Investors

Arch Venture Partners (Keith Crandell)

private investors (Hansjoerg Wyss)

Proceeds Purpose
In addition to the Series A funding, Ultivue has received an exclusive license from Harvard University for the Wyss Institute's DNA-PAINT and DNA-Exchange technologies and acquired the rights to other key enabling technology from California Institute of Technology.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
763D Concord Ave.
Cambridge, MA 02138
USA
Email Address
Overview
Ultivue is an early stage life sciences tools company that seeks to provide the ultimate view into biology. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that vastly improve our understanding of biology and medicine.
Profile
Ultivue LinkedIn Company Profile
Social Media
Ultivue Company Twitter Account
Company News
Ultivue News
Facebook
Ultivue on Facebook
YouTube
Ultivue on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Jacques Corriveau
  Jacques Corriveau LinkedIn Profile  Jacques Corriveau Twitter Account  Jacques Corriveau News  Jacques Corriveau on Facebook
Chief Financial Officer
Richard Malabre
  Richard Malabre LinkedIn Profile  Richard Malabre Twitter Account  Richard Malabre News  Richard Malabre on Facebook
Chief Medical Officer
Keith Wharton
  Keith Wharton LinkedIn Profile  Keith Wharton Twitter Account  Keith Wharton News  Keith Wharton on Facebook
VP - Bus. Development
Mark Rees
  Mark Rees LinkedIn Profile  Mark Rees Twitter Account  Mark Rees News  Mark Rees on Facebook
VP - Finance
Anna Pevzner
  Anna Pevzner LinkedIn Profile  Anna Pevzner Twitter Account  Anna Pevzner News  Anna Pevzner on Facebook
VP - General Counsel
Pamela Guy
  Pamela Guy LinkedIn Profile  Pamela Guy Twitter Account  Pamela Guy News  Pamela Guy on Facebook
VP - Human Resources
Siobhan Desmond
  Siobhan Desmond LinkedIn Profile  Siobhan Desmond Twitter Account  Siobhan Desmond News  Siobhan Desmond on Facebook
VP - Product Management
James Drummey
  James Drummey LinkedIn Profile  James Drummey Twitter Account  James Drummey News  James Drummey on Facebook
VP - R & D
Michael Sismour
  Michael Sismour LinkedIn Profile  Michael Sismour Twitter Account  Michael Sismour News  Michael Sismour on Facebook
VP - Sales
Barry Lynch
  Barry Lynch LinkedIn Profile  Barry Lynch Twitter Account  Barry Lynch News  Barry Lynch on Facebook


 

 

Browse more venture capital transactions:

Prev: 10/14/2015: Astute Medical venture capital transaction
Next: 10/14/2015: Kabbage venture capital transaction

 

Share this article

 


News on VC Transactions

We do our best to record every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary